# Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Study · id `cardio:ct-nct02036515` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02036515](<https://clinicaltrials.gov/study/NCT02036515>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02036515

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 464 participants.

## Technical summary

Registry record NCT02036515. Randomized; double masking; primary purpose treatment. Start 2014-03-12 (actual); primary completion 2016-06-06 (actual). Results posted on 2017-07-24.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 464 participants (enrolled count; ClinicalTrials.gov record NCT02036515, source copy `cardio:ctgov-nct02036515-2018-09-13`, retrieved 2026-10-26)
- Started: 2014-03-12 (actual) (ClinicalTrials.gov record NCT02036515, source copy `cardio:ctgov-nct02036515-2018-09-13`, retrieved 2026-10-26)
- Primary completion: 2016-06-06 (actual) (ClinicalTrials.gov record NCT02036515, source copy `cardio:ctgov-nct02036515-2018-09-13`, retrieved 2026-10-26)
- Completion: 2016-06-06 (actual) (ClinicalTrials.gov record NCT02036515, source copy `cardio:ctgov-nct02036515-2018-09-13`, retrieved 2026-10-26)
- Results first posted: 2017-07-24 (ClinicalTrials.gov record NCT02036515, source copy `cardio:ctgov-nct02036515-2018-09-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02036515-2018-09-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ertugliflozin 5 mg
- Intervention (Drug): Ertugliflozin 15 mg
- Intervention (Drug): Placebo for ertugliflozin 5 mg
- Intervention (Drug): Metformin
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Glimepiride
- Intervention (Biological): Insulin
- Intervention (Drug): Placebo for ertugliflozin 10 mg
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study (`cardio:pubmed-28921862`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 380af673238c1d0bae14410b1667d539b585e01dde2fc5a812358ca241a591b7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
